These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 25563977

  • 1. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2019 Feb 10; 556():172-180. PubMed ID: 30553002
    [Abstract] [Full Text] [Related]

  • 5. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2018 Nov 10; 137():47-55. PubMed ID: 30253203
    [Abstract] [Full Text] [Related]

  • 6. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jan 10; 32(1):37-46. PubMed ID: 24962512
    [Abstract] [Full Text] [Related]

  • 7. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
    Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2018 Mar 10; 129():414-423. PubMed ID: 29155017
    [Abstract] [Full Text] [Related]

  • 8. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 9. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2014 Mar 15; 134(6):1484-94. PubMed ID: 24037730
    [Abstract] [Full Text] [Related]

  • 10. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
    van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Mol Pharm; 2018 Nov 05; 15(11):5124-5134. PubMed ID: 30247919
    [Abstract] [Full Text] [Related]

  • 11. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2009 Apr 01; 15(7):2344-51. PubMed ID: 19276246
    [Abstract] [Full Text] [Related]

  • 12. ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.
    Martínez-Chávez A, Loos NHC, Lebre MC, Tibben MM, Rosing H, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2022 Apr 01; 178():105954. PubMed ID: 34700018
    [Abstract] [Full Text] [Related]

  • 13. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Pharm; 2017 Oct 02; 14(10):3258-3268. PubMed ID: 28880088
    [Abstract] [Full Text] [Related]

  • 14. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Pharm; 2012 Nov 05; 9(11):3236-45. PubMed ID: 23020847
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2020 Mar 15; 146(6):1631-1642. PubMed ID: 31304590
    [Abstract] [Full Text] [Related]

  • 17. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.
    Mol Pharm; 2019 Sep 03; 16(9):3842-3852. PubMed ID: 31329454
    [Abstract] [Full Text] [Related]

  • 18. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.
    Nucl Med Biol; 2015 Nov 03; 42(11):833-41. PubMed ID: 26264927
    [Abstract] [Full Text] [Related]

  • 19. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.
    Wang Y, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.
    Br J Pharmacol; 2020 Jul 03; 177(13):3060-3074. PubMed ID: 32087611
    [Abstract] [Full Text] [Related]

  • 20. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
    van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2019 Aug 03; 146():104297. PubMed ID: 31175939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.